Detalles de la búsqueda
1.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561010
2.
Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.
Future Oncol
; 18(17): 2087-2099, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240857
3.
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Int J Clin Oncol
; 27(12): 1805-1817, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36264378
4.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet
; 393(10167): 156-167, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30509740
5.
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Breast Cancer Res Treat
; 165(2): 375-382, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623430
6.
p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Lancet
; 394(10206): 1323, 2019 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31609223
7.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Lancet Oncol
; 15(10): 1137-46, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25130998
8.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
J Clin Oncol
; 41(4): 790-802, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36219809
9.
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629.
Dermatol Ther (Heidelb)
; 13(12): 3165-3180, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943491
10.
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
J Clin Oncol
; 40(21): 2321-2332, 2022 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35333599
11.
Circulating tumor cells in breast cancer: a tool whose time has come of age.
BMC Med
; 9: 43, 2011 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-21510857
12.
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
J Natl Cancer Inst
; 113(2): 171-181, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32407532
13.
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Dermatol Ther (Heidelb)
; 11(5): 1777-1790, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34558040
14.
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).
J Clin Oncol
; 38(25): 2916-2925, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673170
15.
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Cancer Res
; 67(4): 1494-501, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17308087
16.
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
Clin Breast Cancer
; 8(2): 124-33, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18621608
17.
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
Cancer Res
; 66(5): 2740-8, 2006 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16510595
18.
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
Int J Radiat Oncol Biol Phys
; 68(2): 347-53, 2007 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17379430
19.
Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.
Clin Pharmacol Drug Dev
; 4(3): 203-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27140800
20.
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.
JAMA Oncol
; 1(3): 369-74, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26114161